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Paxillin is a focal-adhesion-associated, tyrosine-phosphorylated
protein. In cells transformed by the src, crk or BCR-Abl
oncogenes, the phosphotyrosine content of paxillin is elevated.
In normal cells paxillin functions in signalling following integrin-
dependent cell adhesion or exposure to a number of stimuli,
including growth factors and neuropeptides. These stimuli induce
tyrosine phosphorylation of paxillin, regulating the association
of Src homology 2 domain-containing signalling molecules with
paxillin. There are multiple sites of tyrosine phosphorylation
on paxillin. To elucidate the role of paxillin in transducing signals
in response to various stimuli, it is essential to identify all of the
sites of phosphorylation on paxillin and to define which residues
are phosphorylated in response to distinct stimuli. We describe
INTRODUCTION
Tyrosine phosphorylation of cytoskeletal proteins in response to
integrin-dependent adhesion is a major mechanism of trans-
ducing signals that control many important biological processes,
including cell motility and cell survival. Cytoskeletal proteins can
also become tyrosine phosphorylated following stimulation with
growth factors or reagents that activate G-protein-coupled
receptors. Several protein tyrosine kinases may be responsible
for phosphorylation of components of the cytoskeleton. The
focal adhesion kinase, FAK, is particularly important in integrin-
mediated signalling, since it prominently co-localizes with the
integrins in focal adhesions and has been implicated in controlling
several integrin-dependent biological events, including motility
and survival [1]. Paxillin is a focal-adhesion-associated, FAK-
binding partner that becomes tyrosine phosphorylated in re-
sponse to multiple stimuli, including cell adhesion [2]. Paxillin is
also heavily phosphorylated on tyrosine in cells transformed by
a number of oncogenes, suggesting it might also have important
functions in the development of cancer [3–5]. Defining how
signalling via paxillin is regulated is critical for the elucidation of
the molecular mechanisms by which normal cells respond to a
range of physiological stimuli, and how these signalling pathways
might be subverted in the development of disease.
Paxillin is a 68 kDa protein that may function as an adaptor
protein, since it contains multiple docking sites for signal-
ling proteins. The N-terminal half of paxillin contains five Leu-
Asp (LD) motifs, which are short peptide sequences that mediate
interactions with other proteins [6]. The LD motifs serve as
binding sites for FAK, cell adhesion kinase β}proline-rich kinase-
2 (‘CAKβ}Pyk2’), vinculin, the E6 oncoprotein of papilloma-
Abbreviations used: SH, Src homology; PDGF, platelet-derived growth factor ; FAK, focal adhesion kinase ; LD motif, Leu-Asp motif ; LIM, an acronym
of the three gene products lin-11, isl-1 and mec-3 ; CE, chicken embryo; DMEM, Dulbecco’s modified Eagle’s medium; FCS, fetal calf serum; TGF,
transforming growth factor ; Ang II, angiotensin II ; RMEM, Richter’s modified Eagle’s medium.
1 To whom correspondence should be addressed (e-mail crispy4!med.unc.edu).
two new sites of tyrosine phosphorylation on paxillin, residues at
positions 40 and 88. Using paxillin variants with phenylalanine
substitutions at phosphorylation sites and phospho-specific
paxillin antibodies, tyrosine phosphorylation of paxillin in re-
sponse to distinct stimuli was examined. The results demonstrate
that Tyr$" and Tyr""), which are binding sites for Crk, are
major sites of tyrosine phosphorylation following cell adhesion
or stimulation with platelet-derived growth factor or angiotensin
II. Thus multiple stimuli may elicit similar signalling events
downstream of paxillin.
Key words: angiotensin, focal adhesions, FAK, integrin, PDGF.
virus and p95 paxillin-kinase linker (‘PKL’) [6,7]. There is a
proline-rich region near the N-terminus of paxillin that can
function as a binding site for the Src homology (SH) 3 domain
of Src [8]. The N-terminal domain of paxillin also contains
a number of tyrosine residues that are candidate sites of
phosphorylation and docking sites for SH2 domain-containing
proteins [5,9–11]. The C-terminal half of paxillin contains four
LIM (an acronym of the three gene products lin-11, isl-1 and
mec-3) domains [5,9]. LIM domains mediate protein–protein
interactions and the third LIM domain contains the major focal-
adhesion-targeting sequence of paxillin [12,13]. The presumed
binding partner responsible for localizing paxillin in focal
adhesions remains to be identified.
The function of paxillin has not been completely elucidated,
but recent work has suggested it controls spreading and motility.
Inhibition of FAK signalling using a dominant-negative strategy
impairs cell spreading on fibronectin and reduced tyrosine
phosphorylation of paxillin was correlated with this effect [14,15].
Tyrosine phosphorylation of paxillin has been implicated in
regulating cell motility in certain scenarios, although the effect
upon motility is controversial. In one report [16], tyrosine
phosphorylation of paxillin appears to promote motility, whereas
another report [17] suggests tyrosine phosphorylation of paxillin
retards cell motility. Further evidence for a role for paxillin in
controlling cell spreading and motility comes from the analysis
of chimaeric integrins. The α
%
integrin subunit binds tightly to
paxillin, both in itro and in io [18]. Expression of a chimaeric





integrin subunits substituted for the natural cytoplasmic
domains, promotes adhesion of Chinese-hamster ovary cells to
fibrinogen. However, this chimaeric receptor does not promote
# 2001 Biochemical Society
58 M. D. Schaller and E. M. Schaefer
spreading on fibrinogen, and the cells exhibit enhanced motility
on fibrinogen relative to cells expressing the wild-type fibrinogen
receptor. A number of lines of evidence demonstrate that paxillin
binding to the α
%
subunit is required to inhibit spreading and
enhance motility of these cells on fibrinogen [18]. In some
situations, paxillin may also play a role in adhesion, since
expression of paxillin mutants containing substitutions at sites of
serine and threonine phosphorylation within the LIM domains
alters cell adhesion to fibronectin [19].
Paxillin becomes tyrosine phosphorylated in response to a
number of stimuli, including cell adhesion and stimulation by
some G-protein-coupled receptors [20]. In addition, levels of
phosphotyrosine are elevated in cells transformed by several
oncogenes, including src, crk and BCR-Abl [3–5]. Tyrosine
phosphorylation of paxillin plays an important role in regulating
the transmission of downstream signals, since expression of
tyrosine-to-phenylalanine substitution mutants of paxillin in-
duces cellular phenotypes that are different from those induced
by expression of wild-type paxillin [16,17]. Tyr$" and Tyr"") have
been identified as sites of phosphorylation in paxillin and serve
as binding sites for Crk [10,11]. Thus signalling downstream of
paxillin is envisioned to involve the recruitment of Crk, and Crk-
associated enzymes like C3G and DOCK180, into a complex
with paxillin. However, there also appears to be additional sites
of tyrosine phosphorylation on paxillin that may mediate the
binding of other SH2 domain-containing proteins that associate
with paxillin, e.g. C-terminal src kinase (‘Csk’) [11,21,22]. In
order to fully elucidate the role of paxillin in signalling, it is
essential to identify all of the sites of phosphorylation of paxillin,
and to determine which sites become phosphorylated in response
to distinct stimuli. We now report that Tyr%! and Tyr)) are
additional sites of paxillin phosphorylation. Using a combination
of tyrosine-to-phenylalanine substitution mutants and phospho-
specific paxillin antibodies, tyrosine phosphorylation of paxillin
in response to different stimuli was examined. Tyr$" and Tyr"")
were found to be major sites of tyrosine phosphorylation
following the adhesion of fibroblasts or smooth-muscle cells to
fibronectin. Interestingly, Tyr)) was required for a shift in the
mobility of paxillin on SDS}polyacrylamide gels. In addition,
Tyr$" and Tyr)) were also shown to be sites of phosphorylation
induced by Ang II stimulation of GN4 cells and platelet-derived
growth factor (PDGF) stimulation of A7r5 cells. Thus multiple
stimuli appear to trigger tyrosine phosphorylation of paxillin
at similar residues to create Crk-binding sites.
EXPERIMENTAL
Cells
Chicken embryo (CE) cells were isolated and maintained in
Dulbecco’s modified Eagle’s medium (DMEM) containing 5%
fetal calf serum (FCS) and 1% chick serum as previously
described [23]. Paxillin and Src were expressed in CE cells using
the RCAS and pRL replication-competent avian retroviral
vectors [23,24]. Plasmid DNA was introduced into CE cells by
transfection [23,24]. The rat A7r5 smooth-muscle-cell line was
obtained from the A.T.C.C. and was maintained in DMEM
supplemented with 10% FCS. Cells were serum-starved for 48 h
in DMEM supplemented with 0±1% FCS prior to stimulation
with 2 ng}ml PDGF (Sigma, St. Louis, MO, U.S.A.) for 10 min
at 37 °C. The rat GN4 liver cell line (provided by Dr Shelton
Earp, Comprehensive Cancer Center University of North
Carolina at Chapel Hill, Chapel Hill, NC, U.S.A.) was main-
tained in Richter’s modified Eagle’s medium (RMEM) supple-
mented with 10% FCS. GN4 cells were serum-starved in RMEM
for 48 h prior to stimulation with 1 µM angiotensin II (Ang II ;
Sigma) for 90 s at 37 °C. To study cell adhesion-dependent
tyrosine phosphorylation, cells were removed from tissue-culture
dishes by trypsinization and the trypsin was inactivated by
washing twice with soybean trypsin inhibitor (Sigma). Cells were
resuspended in serum-free DMEM, held in suspension at 37 °C
and plated on to Petri dishes coated with fibronectin as previously
described [25,26].
Molecular biology
A fragment of the paxillin cDNA extending from the 5« end to
the SacI site at nucleotide 705 was subcloned into the pAlter
vector (Promega, Madison, WI, U.S.A.) for mutagenesis. Oligo-
nucleotide-directed mutagenesis was performed to introduce
substitutions into the paxillin cDNA. Mutant clones were
detected by nucleotide sequencing. For expression in Escherichia
coli the paxillin inserts from the pAlter plasmids were amplified
by PCR using a 5« primer that removed the initiation codon and
engineered a BamHI restriction site. The BamHI site was designed
so that the paxillin sequences would be in-frame with the start
codon and histidine tag found in the pRSET vector. The 3«
primer annealed downstream of the paxillin insert and the
BamHI site of the multiple cloning site of pAlter. The ampli-
fication product was cleaved with BamHI and inserted into the
BamHI site of pRSET B (Invitrogen, San Diego, CA, U.S.A.).
For expression in avian cells, the fragment of the mutant paxillin
cDNAs extending from the EcoRI site (at the 5« end of
the cDNA) to the SacI site (at nucleotide 705) were excised from
pAlter and substituted for the corresponding wild-type sequence
in the plasmid pBSctag}paxillin [24]. The 3« end of the paxillin
coding sequences in this plasmid is fused in-frame with sequences
encoding the KT3 epitope tag. Each of the pRSET}paxillin and
pBSctag}paxillin constructs were subjected to nucleotide
sequencing analysis to verify that the targeted mutations were
present, and that no unintended mutations were introduced into
the constructs. Nucleotide sequencing was performed using a
Sequenase kit (Amersham Pharmacia Biotech, Piscataway, NJ,
U.S.A.). The mutated, epitope-tagged inserts from the pBSctag}
paxillin constructs were subcloned into the RCAS A avian,
replication competent, retroviral vector.
Phosphopeptide analysis
pRSET derivatives were introduced into E. coli JM109. Ex-
pression was induced by addition of isopropyl β--thio-
galactoside and infection with recombinant M13 bacterio-
phage engineered to express the T7 polymerase (Invitrogen).
Bacterial lysates were incubated with a commercially available
paxillin monoclonal antibody (Transduction Laboratories, San
Diego, CA, U.S.A.), and the recombinant paxillin fragments
phosphorylated by Src in an in itro kinase assay. Src was
immunoprecipitated from CE cell lysates expressing the activated
mutant Src&#(F using the monoclonal antibody EC10 (a gift from
Dr Sally Parsons, Department of Microbiology University of
Virginia, Charlottesville, VA, U.S.A.). Immune complexes con-
taining the recombinant fragments of paxillin were mixed with
Src-containing immune complexes and co-precipitated using
Protein A–Sepharose coated with anti-mouse IgG antibodies.
The resulting immunoprecipitates were incubated in an in itro
kinase assay as described previously [11]. As a control, full-length
wild-type paxillin, endogenously expressed in CE cells, was
immunoprecipitated and analysed in parallel. Samples were
analysed by SDS}PAGE and transferred on to nitrocellulose
membranes. Radiolabelled paxillin was visualized by autoradio-
graphy. The bands were excised, trypsinized and phosphopeptide
analysis was performed as described previously [11]. A synthetic
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peptide mimicking the tryptic peptide of paxillin containing
Tyr)) (YGHQQPQSQSPIYSSSAK; Biosource International,
Camarillo, CA, U.S.A.) was phosphorylated by Src in an in itro
kinase assay and purified by high voltage electrophoresis as
described previously [11]. The phosphorylated peptide was then
analysed by high voltage electrophoresis and chromatography
[11].
Protein analysis
Cells were lysed on ice in RIPA buffer [50 mM Tris (pH 7±3)}
150 mM NaCl}1% Triton X-100}0±5% deoxycholate] contain-
ing protease and phosphatase inhibitors [24]. Exogenously
expressed paxillin was immunoprecipitated using the KT3 mono-
clonal antibody. Endogenous paxillin was immunoprecipitated
using the 8605 polyclonal antiserum [24]. Paxillin was immuno-
precipitated, the samples eluted in Laemmli sample buffer and
analysed by Western blotting as described previously [24,27].
Membranes were blocked with 10 mM Tris (pH 7±5)}150 mM
NaC1}0±1% Tween 20 containing 5% (w}v) powdered milk
(for blots to detect proteins) or 5% (w}v) BSA (for blots to
detect phosphotyrosine and blots using phospho-specific anti-
bodies). KT3 and a polyclonal paxillin antiserum were used to
detect paxillin [24]. RC20 (Transduction Laboratories) was used
for the detection of phosphotyrosine. Phospho-specific paxillin
antibodies that recognize paxillin when phosphorylated on Tyr$"
(PY31) or Tyr"") (PY118) (Biosource International), were used
for Western blotting in this analysis. These affinity purified
(using both negative and positive affinity purification methods)
rabbit polyclonal antibodies have been shown to be highly
selective for the targeted phosphorylation site, as demonstrated
by peptide competition studies. The phospho-specific paxillin
antibodies were used at approx. 0±3 µg}ml. Horseradish
peroxidase-conjugated Protein A (1:1000; Amersham Pharmacia
Biotech) was used as a secondary reagent to detect the phospho-
specific antibodies. Enhanced chemiluminescence was used as the
detection system following Western blotting (Amersham
Pharmacia Biotech).
RESULTS
Identification of additional sites of tyrosine phosphorylation in
paxillin
The tryptic phosphopeptide map of paxillin phosphorylated in
itro by Src contains three major phosphopeptides : peptide a,
which contains Tyr$" and Tyr%!, peptide b, which contains Tyr"")
and peptide c, which has not been characterized [11]. To identify
the site of phosphorylation in peptide c, the radiolabelled tryptic
phosphopeptide was isolated from a TLC plate and analysed by
automatedEdmandegradation sequencing [11]. The radioactivity
incorporated into peptide c was released in sequencing cycle 13
(results not shown). Examination of the predicted amino acid
sequence of paxillin revealed only one tyrosine residue that was
13 amino acids downstream of a tryptic cleavage site, Tyr)). This
result suggests that phosphopeptide c is phosphorylated on Tyr))
of paxillin.
To further analyse tyrosinephosphorylationofpaxillin, phenyl-
alanine substitutions were made for each of four candidate
tyrosine phosphorylation sites of paxillin (Tyr$", Tyr%!, Tyr)) and
Tyr"")), either alone or in combination, using oligonucleotide-
directedmutagenesis. To study tyrosine phosphorylation of paxil-
lin mutants in itro, the NH
#
-terminal fragment of each
paxillin variant, containing the first 238 residues, was expressed
as a recombinant protein in E. coli using the pRSET expression
system. Although the yield of protein was very low, sufficient
material was obtained to perform the analysis. The recombinant
proteins were captured from bacterial lysates using a monoclonal
antibody and mixed immune complexes containing the recom-
binant paxillin and Src (isolated from CE cell lysates) proteins
were formed. The resulting immune complexes were incubated in
an in itro kinase assay under conditions that were previously
shown to phosphorylate paxillin on the same tyrosine residues
that are phosphorylated in io [11]. All of the mutants containing
a single phenylalanine-for-tyrosine substitution (paxillinY$"F,
paxillinY%!F, paxillinY))F, paxillinY"")F ) were phosphorylated by
Src in itro (Figure 1, lanes 3–6). Src also phosphorylated
paxillinY$"F/Y%!F, which contains substitutions of phenylalanine
for Tyr$" and Tyr%! and paxillinY$"F/Y"")F, which contains substi-
tutions of phenylalanine for Tyr$" and Tyr"") (Figure 1, lanes 7
and 8). In contrast, Src did not phosphorylate paxillin%F, which
contains phenylalanine substitutions for Tyr$", Tyr%!, Tyr)) and
Tyr"") (Figure 1, lane 9). This result suggests that tyrosine
phosphorylation of the NH
#
-terminal domain of paxillin by Src
is restricted to these four residues and that tyrosine
phosphorylation of another potential phosphorylation site,
Tyr")" [5,9], is negligible under the conditions of the assay.
The paxillin mutants were further analysed by phosphopeptide
mapping. Initially, the phosphopeptide maps of paxillin isolated
from CE cells and the recombinant fragment of wild-type paxillin
were compared and found to be identical (results not shown).
The map of paxillinY))F contained the two major peptides a and
b, but was missing peptide c (Figure 2B). This result indicates
that Tyr)) is a site of phosphorylation by Src in itro. To further
substantiate this conclusion, a synthetic peptide identical in
sequence to the predicted tryptic peptide of paxillin containing
Tyr)) was analysed. The peptide was phosphorylated by Src in
itro and analysed by high voltage electrophoresis and chromato-
graphy. The major spot in the phosphopeptide map exhibited
electrophoretic and chromatographic properties similar to pep-
tide c (Figure 2C, arrow). To determine if the phosphorylated
synthetic peptide co-migrated with peptide c, the samples in
Figures 2(A) and (C) were mixed and analysed. The resulting
map exhibited the same three major phosphopeptides found in
panel A (Figure 2D). Further, in the mixture the intensity of
peptide c was elevated compared with the intensity of peptide c
in Figure 2(A). These observations demonstrate that the synthetic
peptide co-migrated with peptide c. These data support the
conclusion that Tyr)) of paxillin is a site of phosphorylation for
Src in itro.
Phosphopeptide maps of the other paxillin mutants were also
examined. The map of paxillinY"")F contained peptides a and c,
but was missing peptide b (results not shown). This result is
consistent with the conclusion that peptide b is phosphorylated
on Tyr"") of paxillin [11]. The phosphopeptide map of paxillinY$"F
was identical with that of wild-type paxillin (Figures 2A and
2E). This result was not completely anticipated since Tyr$" was
previously identified as a site of phosphorylation [11]. However,
there was also evidence that this peptide might contain a second
phosphorylated tyrosine residue, Tyr%!. The phosphopeptide
map of paxillinY%!F was also identical to the map of wild-type
paxillin (Figures 2A and 2F). However, mutation of both
Try$" and Tyr%" (in paxillinY$"F/Y%!F) resulted in the loss of
peptide a from the phosphopeptide map (Figure 2G). These
results demonstrate that this peptide indeed contains two tyrosine
residues that can be phosphorylated by Src in itro.
Tyrosine phosphorylation of paxillin mutants in vivo
In order to examine tyrosine phosphorylation of the paxillin
mutants in io each was engineered into full-length, epitope-
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Figure 1 Tyrosine phosphorylation of recombinant paxillin fragments in vitro by Src
Src immune complexes were incubated in an in vitro protein kinase assay either alone (lane 1) or after mixing with immune complexes containing paxillin substrates (lanes 2–9). Full-length avian
paxillin was immunoprecipitated from a CE cell lysate (lane 2). Recombinant fragments of paxillin mutants, including Y31F (lane 3), Y40F (lane 4), Y88F (lane 5), Y118F (lane 6), Y31F/Y40F
(lane 7), Y31F/Y118F (lane 8) and 4F (lane 9), were expressed in E. coli and immunoprecipitated from E. coli lysates. Kinase reactions were terminated by addition of Laemmli sample buffer
and the samples analysed by SDS/PAGE and autoradiography. The positions of the full-length avian paxillin, Src and the recombinant paxillin fragments are indicated.
Figure 2 Phosphopeptide mapping of paxillin
Full-length avian paxillin (A) and the recombinant fragments of paxillin mutants Y88F (B), Y31F (E), Y40F (F) and Y31F/Y40F (G) were radiolabelled by Src in vitro as in Figure 1. The proteins
were transferred on to nitrocellulose, trypsinized and analysed by high-voltage electrophoresis and chromatography as previously described [11]. Phosphopeptides a, b and c are identified by
arrows in (A). A synthetic peptide mimicking the predicted tryptic peptide containing Tyr88 of paxillin was labelled by Src in vitro and purified by high-voltage electrophoresis on a TLC plate as
described in [11]. The peptide was then analysed by-high voltage electrophoresis and chromatography (C). A mixture of the samples from (A) and (C) were analysed in (D). The directions of
electrophoresis and chromatography are indicated. The solid circle indicates the origin on the TLC plate.
tagged paxillin and subcloned into the RCAS A replication-
competent retroviral vector. The mutants were expressed in CE
cells. Exogenously expressed paxillin was immunoprecipitated
using an antibody recognizing the KT3 epitope tag and tyrosine
phosphorylation was examined by Western blotting. Epitope-
tagged wild-type paxillin was tyrosine phosphorylated (Figures
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Figure 3 Expression and tyrosine phosphorylation of paxillin mutants in CE cells
Epitope-tagged paxillin constructs were expressed in CE cells using the RCAS A vector. (A) Cells transfected with the empty vector (lane 1) or with RCAS A containing wild-type paxillin (lane
2), paxillinY31F (lane 3), paxillinY40F (lane 4), paxillinY88F (lane 5), paxillinY118F (lane 6), paxillinY31F/Y40F (lane 7), paxillinY31F/Y118F (lane 8) or paxillin4F (lane 9) were lysed. Exogenous paxillin was
immunoprecipitated with KT3, which recognizes the epitope tag, and the samples were analysed by Western blotting for phosphotyrosine ( ptyr ; upper panel). The blot was stripped and reprobed
with a paxillin polyclonal antiserum as a loading control (lower panel). (B) Cells transfected with the empty vector (lane 1) or with RCAS A containing wild-type paxillin (lane 2), paxillin4F (lane
3), paxillin3F31Y (lane 4), paxillin3F88Y (lane 5) or paxillin3F118Y (lane 6) were lysed and analysed as in (A). The phosphotyrosine Western-blot ( ptyr ; upper panel) was stripped and reprobed with
KT3 (lower panel) as a loading control.
3A and 3B, lanes 2) [24]. In contrast, paxillin%F contained no
detectable tyrosine phosphorylation (Figures 3A, lane 9 and 3B,
lane 3). Thus in cells growing in tissue culture, tyrosine phos-
phorylation of paxillin was restricted to these four tyrosine
residues. Tyr$" was a major site of phosphorylation on paxillin
since paxillin$"F exhibited a very dramatic reduction in the
amount of phosphotyrosine relative to wild-type paxillin (Figure
3A, lane 3). In addition, paxillin$F$"Y, which has phenylalanine
substitutions at Tyr%!, Tyr)) and Tyr""), still exhibits substantial
tyrosine phosphorylation (Figure 3B, lane 4). However, there are
clearly other tyrosine-phosphorylated residues, since paxillin$"F
is not devoid of phosphotyrosine and paxillin$F$"Y does not
exhibit wild-type levels of phosphotyrosine (Figures 3A, lane 3
and 3B, lane 4). Tyr"") was a second site of phosphorylation as
shown by the reduction in tyrosine phosphorylation of
paxillinY"")F relative to wild-type paxillin (Figure 3A, lane 6). In
addition, paxillin$F"")Y, which has substitutions for Tyr$", Tyr%!
and Tyr)), contains phosphotyrosine (Figure 3B, lane 6).
Tyr$" and Tyr"") appeared to be the predominant sites of
phosphorylation in io since paxillinY$"F/Y"")F exhibited very
dramatically reduced levels of phosphotyrosine relative to wild-
type paxillin (Figure 3A, lane 8). Nevertheless, there are other
tyrosine residues that were phosphorylated, since
paxillinY$"F/Y"")F was still not devoid of phosphotyrosine. In
contrast, there was little difference in the phosphotyrosine levels
of wild-type paxillin and paxillinY%!F, suggesting that this may be
a minor site of phosphorylation in CE cells (Figure 3A, lane
4). PaxillinY))F was also prominently phosphorylated on tyro-
sine (Figure 3A, lane 5). However, in contrast with tyrosine
phosphorylated wild-type paxillin, which exhibited a hetero-
geneous electrophoretic mobility (Figure 3A, lane 2), tyrosine
phosphorylated paxillinY))F migrated as a tight band on the gel
(Figure 3A, lane 5). Thus phosphorylation at Tyr)) may con-
tribute to the retarded electrophoretic mobility characteristic of
tyrosine-phosphorylated paxillin. There is very little tyrosine
phosphorylation detected on paxillin$F))Y, which has substi-
tutions for Tyr$", Tyr%! and Tyr""), suggesting that Tyr)) may be
a minor site of phosphorylation (Figure 3B, lane 5). The
phosphotyrosine Western blots were stripped and reprobed with
a paxillin polyclonal antiserum (Figure 3A, bottom panel) or
with KT3 (Figure 3B, bottom panel) to verify that the observed
differences in tyrosine phosphorylation were not due to
differential recovery of protein.
Tyrosine phosphorylation of paxillin mutants following adhesion to
fibronectin
A major stimulus controlling tyrosine phosphorylation of paxillin
is integrin-dependent cell adhesion. To explore the regulation of
tyrosine phosphorylation of the mutants, cells were trypsinized,
held in suspension and plated on to fibronectin-coated dishes.
Cells were lysed after incubation at 37 °C for 60 min. The
exogenously expressed paxillin was immunoprecipitated using
KT3 and analysed for phosphotyrosine by Western blotting. As
previously described, tyrosine phosphorylation of wild-type
epitope-tagged paxillin was regulated by cell adhesion [24] (Figure
4, lanes 1–3). Tyrosine phosphorylation disappeared when cells
were taken into suspension and then returned upon plating the
# 2001 Biochemical Society
62 M. D. Schaller and E. M. Schaefer
Figure 4 Tyrosine phosphorylation of paxillin mutants in response to cell adhesion
Cells expressing wild-type paxillin (lanes 1–3), paxillin4F (lanes 4–6), paxillinY31F (lanes 7–9), paxillinY40F (lanes 10–12), paxillinY88F (lanes 13–15), paxillinY118F (lanes 16–18), paxillin3F31Y (lanes
19–21), paxillin3F88Y (lanes 22–24) or paxillin3F118Y (lanes 25–27) were held in suspension (lanes 2, 5, 8, 11, 14, 17, 20, 23 and 26) or plated on to fibronectin for 1 h (lanes 3, 6, 9, 12, 15,
18, 21, 24 and 27) prior to lysis. Cells growing in culture were lysed as controls (lanes 1, 4, 7, 10, 13, 16, 19, 22 and 25). Exogenously expressed paxillin was immunoprecipitated using KT3
and Western-blotted with a phosphotyrosine antibody (ptyr ; top panels). The blots were stripped and reprobed with KT3 as a loading control (bottom panels).
cells on fibronectin. Paxillin%F was devoid of phosphotyrosine
in cells growing in culture and did not become tyrosine
phosphorylated upon adhesion to fibronectin (Figure 4, lanes
4–6). Thus cell adhesion-dependent tyrosine phosphorylation
appears to be restricted to the four sites of phosphoryl-
ation identified in the N-terminal half of paxillin (Tyr$", Tyr%!,
Tyr)) and Tyr"")). A major site of cell adhesion-dependent tyro-
sine phosphorylation of paxillin in CE cells was Tyr$". PaxillinY$"F
exhibited a dramatic decrease in the level of tyrosine
phosphorylation following cell adhesion when compared with
wild-type paxillin (Figure 4, lanes 7–9). PaxillinY"")F also
exhibited a decrease in tyrosine phosphorylation following ad-
hesion to fibronectin, suggesting that Tyr"") also becomes
phosphorylated in response to cell adhesion (Figure 4, lanes
16–18). In addition, both paxillin$F$"Y and paxillin$F"")Y became
tyrosine phosphorylated following adhesion to fibronectin (Fig-
ure 4, lanes 19–21 and 25–27, respectively). PaxillinY%!F showed
little reduction in tyrosine phosphorylation following adhesion
relative to levels seen in the wild-type protein (Figure 4, lanes
10–11). Again, this argues that Tyr%! is, at best, a minor site of
phosphorylation following adhesion of CE cells to fibronectin.
PaxillinY))F also became tyrosine phosphorylated after plating on
fibronectin (Figure 4, lanes 13–15). Although the intensity of the
signal appeared equal to, or even greater than, that of wild-type
paxillin, it was striking that only a single species of paxillinY))F
was detected (Figure 4, lane 15). This contrasts with the multiple
isomers of tyrosine-phosphorylated paxillin, appearing as a broad
heterogeneous band on the blot, found with each of the other
constructs. This observation suggests that Tyr)) is required for a
change in the electrophoretic mobility of paxillin following cell
adhesion.
Characterization of phospho-specific paxillin antibodies
The substitution mutants described here have been utilized
to characterize two phosphorylation site-specific antibodies to
paxillin. PY31 is directed against tyrosine-phosphorylated resi-
due at position 31 and PY118 is directed against tyrosine-
phosphorylated residue at position 118. For this analysis, paxillin
mutants were expressed in CE cells and the cells were treated
with 50 mM pervanadate for 30 min to stimulate maximum
tyrosine phosphorylation. Themutants were immunoprecipitated
from cell lysates using KT3 and the proteins analysed by Western
blotting. For comparison, endogenous paxillin was immuno-
precipitated from lysates of CE cells that were not pervanadate
treated and analysed in parallel. Note that the amount of
endogenous paxillin analysed corresponds to the amount
immunoprecipitated from 500 µg of lysate, and the amount of
exogenous paxillin corresponds to the amount immuno-
precipitated from 20 µg of lysate from pervanadate-treated cells.
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Figure 5 Characterization of phospho-specific paxillin antibodies
Cells expressing wild-type paxillin (lane 2), paxillin4F (lane 3), paxillinY31F (lane 4), paxillinY118F
(lane 5), paxillin3F31Y (lane 6) or paxillin3F118Y (lane 7) were treated with pervanadate (50 mM
for 30 min) prior to lysis. Exogenous paxillin was immunoprecipitated using KT3. A small
fraction of the immune complex, equivalent to the amount of protein from approx. 20 µg of cell
lysate, was loaded in each lane. Endogenous, wild-type paxillin was immunoprecipitated from
500 µg of CE cell lysate and analysed in parallel (lane 1). Immune complexes were analysed
by Western blotting for phosphotyrosine ( ptyr ; A), a phospho-specific antibody designed to
recognize phosphorylated Tyr31 of paxillin (PY31 ; B) and a phospho-specific antibody designed
to recognize phosphorylated Tyr118 of paxillin (PY118 ; C). The phosphotyrosine Western blot
in (A) was stripped and reprobed with a paxillin polyclonal antiserum as a loading control (D).
Initially, total tyrosine phosphorylation of paxillin was examined
by Western blotting with a generic phosphotyrosine antibody
(Figure 5A). Comparable levels of tyrosine phosphorylation
were seen on wild-type paxillin, paxillinY$"F and paxillinY"")F
(Figure 5A, lanes 2, 4 and 5). Paxillin$F$"Y and paxillin$F"")Y were
also tyrosine phosphorylated, although to a reduced level relative
to the other mutants (Figure 5A, lanes 6 and 7). Paxillin%F
exhibited a very low level of phosphotyrosine, suggesting that
paxillin may contain a site(s) of tyrosine phosphorylation in
addition to the four mapped sites (Figure 5A, lane 3). However,
since the signal is very low and phosphorylation of this site(s) can
only be detected following pervanadate treatment, it is likely to
be a very minor site(s) of phosphorylation. Due to the ex-
perimental set up and differential loading of endogenous and
exogenously expressed paxillin, similar levels of phosphotyrosine
were detected on endogenous paxillin and exogenous wild-type
paxillin (Figure 5A, lanes 1 and 2). Note the decrease in relative
mobility of paxillin following pervanadate treatment (Figure
5A). The antibody PY31 specifically recognized paxillin that was
phosphorylated on Tyr$". The antibody reacted with endogen-
ous paxillin and exogenously expressed wild-type paxillin,
paxillinY"")F and paxillin$F$"Y (Figure 5B, lanes 1, 2, 5 and 6). In
contrast, the antibody did not react with paxillin%F, paxillinY$"F
or paxillin$F"")Y (Figure 5B, lanes 3, 4 and 7). Similarly, the
antibody PY118 specifically reacted with paxillin that was
phosphorylated on Tyr""). This antibody recognized endogen-
ous paxillin and exogenously expressed wild-type paxillin,
paxillinY$"F, and paxillin$F"")Y (Figure 5C, lanes 1, 2, 4 and 7), but
did not react with paxillin%F, paxillinY"")F or paxillin$F$"Y (Figure
5C, lanes 3, 5 and 6). These results demonstrate that the PY31
and PY118 antibodies specifically recognize the appropriate
tyrosine-phosphorylated isomers of paxillin by Western-blot
analysis.
Cell adhesion-dependent tyrosine phosphorylation of residues at
positions 31 and 118 of paxillin
To explore tyrosine phosphorylation of endogenous paxillin
in response to cell adhesion, CE cells were trypsinized, held in
suspension and plated on to fibronectin-coated dishes. After
incubation at 37 °C for various times, cells were lysed and
paxillin was immunoprecipitated and analysed by Western blot-
ting. To again verify the specificity of the PY31 and PY118
phospho-specific antibodies in these experiments, paxillin
mutants were also immunoprecipitated from pervanadate-treated
cells using KT3 and analysed in parallel. When cells were taken
into suspension, the phosphotyrosine content of paxillin dis-
appeared (Figure 6A, lane 2). Tyrosine phosphorylation rapidly
reappeared upon adhesion to fibronectin, although the level of
phosphorylation did not reach the level of phosphorylation seen
in culture even after 90 min on fibronectin in serum-free medium
(Figure 6A, lanes 3–7). Since the level of tyrosine phosphorylation
of paxillin plated on to fibronectin was reduced relative to the
level of phosphorylation seen in cells growing in culture (Figure
6A, lane 1 versus lanes 3–7), it seemed possible that other factors
affecting the cells in culture, e.g. the presence of serum
factors, contributed to tyrosine phosphorylation of paxillin. To
determine if serum stimulation enhanced tyrosine phosphoryl-
ation of paxillin in cells plated on fibronectin, cells that had
adhered to fibronectin for 80 min were stimulated with 20% FCS
for 10 min prior to lysis. Under these conditions, serum stimu-
lation induced only a small increase in tyrosine phosphorylation
of paxillin (Figure 6A, lane 8). Phosphorylation of Tyr$" and
Tyr"") was examined by Western blotting using the PY31 and
PY118 phospho-specific antibodies. Both residues were phos-
phorylated in cells growing in culture and became dephosphoryl-
ated when the cells were taken into suspension (Figures 6B and
6C, lanes 1 and 2). Adhesion to fibronectin resulted in
phosphorylation of both Tyr$" and Tyr"") (Figures 6B and
6C, lanes 3–7). Stimulation of fibronectin-adhered cells with
serum resulted in little change in the level of phosphorylation
of these sites (Figures 6B and 6C, lanes 8). As a control,
the phosphotyrosine Western blot was stripped and reprobed
with a paxillin polyclonal antiserum to verify that equal levels
of protein were present (Figure 6D). To investigate whether
Tyr$" and Tyr"") were cell adhesion-dependent sites of phos-
phorylation in other cell types, a similar analysis was performed
on A7r5 smooth-muscle cells. As observed in CE cells, Tyr$"
and Tyr"") also became phosphorylated upon adhesion of
A7r5 cells to fibronectin (results not shown). These results
demonstrate that phosphorylation of Tyr$" and Tyr"") of
endogenous paxillin is regulated in a cell adhesion-dependent
fashion.
Phosphorylation of Tyr31 and Tyr118 in response to other stimuli
In addition to cell adhesion-dependent regulation, tyrosine
phosphorylation of paxillin is induced by exposure of cells to
other stimuli. For example, stimulation of smooth-muscle cells
with PDGF induces tyrosine phosphorylation of paxillin, as does
stimulation of the GN4 liver cell line with Ang II [28–30].
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Figure 6 Analysis of cell adhesion-dependent tyrosine phosphorylation of
paxillin in CE cells using phospho-specific antibodies
CE cells were held in suspension (lanes 2), or plated on to fibronectin for various times prior
to lysis (lanes 3–8). One sample was plated on to fibronectin for 80 min, then stimulated with
20% FCS for 10 min prior to lysis (lanes 8). As a control, CE cells growing in culture were
analysed in parallel (lanes 1). Paxillin was immunoprecipitated using a polyclonal antiserum and
the immune complexes analysed by Western blotting using a phosphotyrosine antibody (ptyr ;
A), PY31 (B) and PY118 (C). As a loading control, the phosphotyrosine Western blot in (A) was
stripped and reprobed with a paxillin polyclonal antiserum (D). As controls for specificity of the
phospho-specific antibodies, KT3 immune complexes from pervanadate-treated cells (50 mM
for 30 min) expressing wild-type paxillin (lane 9), paxillin4F (lane 10), paxillinY31F (lane 11) or
paxillinY118F (lane 12) were also examined by Western blotting.
Therefore the phospho-specific paxillin antibodies were used to
analyse phosphorylation of paxillin at Tyr$" and Tyr"") in
response to additional stimuli. Following serum starvation, A7r5
cells were stimulated with PDGF and tyrosine phosphorylation
of paxillin was analysed by immunoprecipitation and Western
blotting. Serum starvation resulted in a decrease in tyrosine
phosphorylation of paxillin as detected with the phospho-
tyrosine antibody or the phospho-specific paxillin antibodies,
although very significant levels of phosphotyrosine remained
(Figures 7A–5C, lanes 5). This presumably reflects the continued
stimulation of paxillin phosphorylation resulting from cell
adhesion to the extracellular matrix proteins. Stimulation with
PDGF caused an increase in tyrosine phosphorylation of paxillin
(Figures 7A–7C, lanes 6). Western blotting for paxillin verified
that changes in phosphorylation did not simply reflect differential
Figure 7 Analysis of paxillin phosphorylation in response to other stimuli
GN4 cells were starved for 48 h in serum-free RMEM (lanes 2) and stimulated with 1 µM Ang
II for 90 s (lanes 3) prior to lysis. Unstarved GN4 cells were used as controls (lanes 1 ; Cul).
A7r5 cells were starved for 48 h in 0±1% FCS (lanes 5) and stimulated with 2 ng/ml PDGF for
10 min (lanes 6) prior to lysis. Unstarved A7r5 cells were used as controls (lanes 4 ; Cul).
Paxillin was immunoprecipitated using a polyclonal antiserum and analysed as described
in Figure 6.
recovery of protein by immunoprecipitation (Figure 7D, lanes
4–6).
Similarly, tyrosine phosphorylation of paxillin in response to
Ang II treatment of GN4 cells was examined. Serum starvation
reduced tyrosine phosphorylation of paxillin as detected by
Western blotting for phosphotyrosine or using the phospho-
specific paxillin antibodies (Figures 7A–7C, lanes 2). However,
this treatment only caused a partial reduction in paxillin
phosphorylation as observed in A7r5 cells, presumably reflecting
adhesion-dependent tyrosine phosphorylation in the starved cells.
Stimulation with Ang II caused increased tyrosine phosphoryl-
ation of paxillin, and the results from the experiments using the
phospho-specific antibodies revealed that both Tyr$" and Tyr"")
become phosphorylated (Figures 7A–7C, lanes 3). The paxillin
Western-blot performed as a loading control again demonstrated
comparable amounts of paxillin in each lane (Figure 7D, lanes
1–3). These results demonstrate that multiple stimuli that induce
tyrosine phosphorylation of paxillin, including cell adhesion,
growth factors and reagents that activate G-protein-coupled
receptors, promote phosphorylation of paxillin at similar tyrosine
residues.
DISCUSSION
In the present study, we describe an analysis of each of the
tyrosine phosphorylation sites of paxillin using a combination of
phosphopeptide mapping, site-directed mutagenesis and phos-
phorylation site-specific antibodies. The most significant finding
is that Tyr$" and Tyr"") on paxillin are the predominant sites
of tyrosine phosphorylation and that diverse stimuli induce
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phosphorylation of these sites. Further, phosphorylation of Tyr$"
and Tyr"") appears to be co-ordinated, since cell adhesion, PDGF
and Ang II induce tyrosine phosphorylation of both sites with
similar kinetics. Recently, prolonged treatment of NMuMG cells
with transforming growth factor (TGF) β1 (inducing an
epithelial-mesenchymal transdifferentiation) was shown to
promote tyrosine phosphorylation of paxillin, predominantly
on Tyr$" and Tyr"") [31]. We also report here the identification of
two additional sites of tyrosine phosphorylation in paxillin, at
positions 40 and 88. Thus each of the identified tyrosine
phosphorylation sites lie near the N-terminus of the protein.
However, in contrast to Tyr$" and Tyr""), these latter two sites
may be minor sites of phosphorylation in io. Nevertheless,
Tyr)) can associate with the SH2 domain of Csk in itro, and thus
phosphorylation of this residue might have physiological
significance [11].
One interesting biochemical characteristic of paxillin is that it
exhibits a heterogeneous electrophoretic mobility. Tyrosine
phosphorylation is likely to retard the electrophoretic mobility of
paxillin, since isomers of paxillin that are heavily tyrosine
phosphorylated exhibit a reduced motility on SDS}polyacryl-
amide gels (Figure 5) [11]. Interestingly, mutation of Tyr)) to
phenylalanine alters the electrophoretic mobility of paxillin,
generating a more homogeneous species. This result suggests that
tyrosine phosphorylation of the residue at position 88 of paxillin
may directly alter the electrophoretic mobility of paxillin. This
would be consistent with the results of phosphorylation by Src in
itro. Phosphorylation of the recombinant fragments of several
paxillin substitution mutants by Src produced several phospho-
isomers. In contrast, tyrosine phosphorylation of the recom-
binant fragment of paxillinY))F did not generate the most retarded
electrophoretic species. Paxillin is also extensively phosphoryl-
ated on serine [11,19,32,33], and there is some evidence suggesting
that phosphorylation of paxillin on serine residues by protein
kinase C may retard the electrophoretic mobility of paxillin [34].
Alternatively, it is also possible that mutation of Tyr)) to
phenylalanine might indirectly affect serine phosphorylation of
paxillin in io and thus indirectly alter the electrophoretic
mobility of paxillin. Further analysis is required to distinguish
these possibilities.
Are there additional sites of tyrosine phosphorylation in
paxillin? In addition to the two Crk-binding sites in paxillin that
were previously identified as sites of phosphorylation (Tyr$" and
Tyr"")) [10,11], there is a third tyrosine residue in paxillin that
conforms to a high affinity Crk-binding site (Tyr")") [5,9]. The
analysis of the paxillin substitution mutants does not support
the hypothesis that Tyr")" is a significant site of phosphorylation
in CE cells. First, tyrosine phosphorylation of the recombinant
fragments of paxillin by Src in itro demonstrated that paxillin%F,
which contains Tyr")", was a very weak substrate for
phosphorylation. Secondly, by phosphopeptide analysis of the
paxillin substitution mutants, each of the phosphotyrosine-
containing tryptic peptides of paxillin was identified and
none contained Tyr")". Finally, paxillin%F was expressed in CE
cells and did not exhibit phosphotyrosine in growing cells or
following adhesion to fibronectin. These observations are con-
sistent with a published finding [35] that indirectly suggests
that Tyr")" is not a site of phosphorylation. Whereas paxillin
variants with substitutions for Tyr$" or Tyr"") abrogated
association with the SH2 domain of CrkL in itro, binding of a
mutant with a substitution for Tyr")" to the CrkL SH2 domain
was similar to wild-type paxillin [35]. In contrast with these
findings, Tyr")" was suggested to be a site of phosphorylation
in NMuMG cells, although it was apparently a minor site
compared with Tyr$" and Tyr"") [31]. Pervandate treatment of
CE cells occasionally induced a very low level of tyrosine
phosphorylation of paxillin%F, suggesting that an additional
site(s) of phosphorylation might exist. However, such a site(s)
would appear to be a very minor site of phosphorylation, and
no evidence for its phosphorylation under physiological con-
ditions was obtained. Therefore it appears that additional
significant sites of tyrosine phosphorylation in paxillin are
unlikely to exist in CE cells.
The main function of tyrosine phosphorylation of paxillin is to
regulate the association of SH2 domain-containing signalling
molecules with paxillin. The two predominant tyrosine
phosphorylation sites, Tyr$" and Tyr""), are both found in a
sequence context conforming to a high affinity Crk SH2 domain-
binding site (YXXP; where X is any amino acid residue), and
these two residues of paxillin have been identified as Crk
and CrkL binding sites [11,35,36]. However, the YXXP motif can
also serve as a docking site for the SH2 domains of Abl and Nck
[36], and glutathione-S-transferase (‘GST’) fusion proteins con-
taining the SH2 domains of Abl and Nck can bind to tyrosine-
phosphorylated paxillin in itro (J. M. Dunty and M. D. Schaller,
unpublished work). Thus tyrosine phosphorylation of residues at
positions 31 and 118 might regulate the recruitment of a number
of proteins into a multifunctional signalling complex.
The observation that different physiological stimuli induce
tyrosine phosphorylation of paxillin at similar tyrosine residues
raises two significant questions. Are similar signalling complexes
assembled following tyrosine phosphorylation of paxillin induced
by different stimuli and, if so, do these complexes perform similar
functions? Although different stimuli might be expected to
promote the formation of similar paxillin containing signalling
complexes, since they induce phosphorylation of the same
tyrosine residues on paxillin, situations can be imagined where
this may not be the case. For example, different stimuli might
induce tyrosine phosphorylation of populations of paxillin found
in distinct cellular compartments. Thus the paxillin-containing
complexes that form in response to different stimuli may depend
upon the subcellular localization of paxillin binding partners.
Alternatively, there may be several mechanisms of regulation of
assembly of specific complexes. In this scenario, only stimuli that
induce paxillin phosphorylation and simultaneously signal to the
paxillin binding partner would promote complex assembly. One
example of a paxillin binding partner exhibiting regulated binding
activity is Crk. There is a site of tyrosine phosphorylation
between the two SH3 domains of Crk that conforms to the
consensus Crk SH2 binding-site. Phosphorylation of this residue
promotes intramolecular binding of the SH2 domain of Crk to
this site, which inhibits the ability of Crk to interact with other
binding partners [37]. Recent evidence from the literature
supports the contention that tyrosine-phosphorylated paxillin
may not always associate with Crk. Whereas adhesion of NBT-
II cells to collagen promoted the interaction of Crk with tyrosine-
phosphorylated paxillin [16], tyrosine-phosphorylated paxillin
failed to associate with Crk or CrkL in NMuMG cells stimulated
with TGF-β [17]. These observations may be functionally signifi-
cant, since tyrosine phosphorylation of paxillin appears to pro-
mote the motility of NBT-II cells and inhibit the motility of
NMuMG cells [16,17]. With this in mind, the next major
challenges in the elucidation of paxillin signalling will be defining
the nature of signalling complexes that are assembled in response
to different stimuli, the subcellular localization of these complexes
and the biochemical and biological responses elicited by these
complexes. Phosphorylation-defective mutants of paxillin, which
have already been shown to function as dominant-negative
mutants [16,17], should greatly aid the dissection of these complex
signalling events.
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